FBR develops life-saving cardiac support devices to help heart disease patients recover in a market worth $12 billion. We intend to lead this heart recovery market.
HEART DISEASE IS THE #1 KILLER
Heart disease is the leading cause of death. To treat heart disease, each year U.S. physicians perform more than two million cardiovascular procedures. Another 400,000 U.S. patients are so sick they cannot even undergo such a life-saving procedure without substantial cardiac support.
NEW CARDIAC SUPPORT DEVICES
New cardiac support devices have emerged that treat heart disease patients and allow them to recover. Most patients recover within hours, and the device is removed.
Our only meaningful competitor was recently acquired for $17B.
HOW FBR WILL LEAD THE HEART RECOVERY FIELD
Our data indicate our low-cost devices may be more effective and associated with fewer complications than our competitor's. FBR has been granted 13 patents and 14 additional patents are pending.
WE HAVE SKIN IN THE GAME
FBR’s founder has invested $5 M developing our products.
OUR SUCCESSFUL RECORD
The previous cardiovascular company our founder started was acquired for $1.1B. In addition, our founder was the first Business Development Manager for Gilead Sciences (NASDAQ: GILD), a pioneering biotechnology company.
Our COO has commercialized more than a dozen medical product platforms. He most recently served as a senior operating officer at Clearpoint Neuro (NASDAQ: CLPT) and Edwards Lifesciences (NASDAQ: EW).
OUR STRONG PROSPECTS
We project that in 2026 we will generate $2.8M of revenue and then grow rapidly. By 2030, we forecast $270M of revenue, $67M of operating income, and $47M of net income.
A COMPELLING VALUATION
Investors are being offered shares at a substantial discount. We believe at this price investors' IRR could exceed 50%.
LOWEST PRICED OFFERING
We believe this will be our lowest priced offering. We anticipate at least one subsequent offering at a higher valuation.